Novo Nordisk Announces Q3 Results and Raises FY2026 Guidance
NVO Novo Nordisk ADR
$41.09 +0.96%
View chart & analysis → - 1Novo Nordisk reported total Q3 net sales of 79.2 billion DKK, a 6% increase year-over-year.
- 2Novo's Q3 Ozempic sales were 29.7 billion DKK, a 3% decrease compared to the same period last year.
- 3Novo Nordisk has raised its guidance for fiscal year 2026.
So what's the key point?
Novo Nordisk's Q3 sales increased to 79.2 billion DKK. The company has raised its earnings outlook for 2026, setting higher expectations for future growth.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.